Publications by authors named "Hua Yi-Jun"

Background: Despite advancements in cancer treatment, understanding the long-term mental health implications for nasopharyngeal carcinoma (NPC) survivors remains an underexplored area. This study aims to examine the prevalence of mental disorders and their correlations with age at diagnosis and time since diagnosis among NPC survivors.

Methods: A total of 1872 NPC patients were surveyed from September 2020 to June 2021 in this cross-sectional survey.

View Article and Find Full Text PDF
Article Synopsis
  • Cisplatin is a common chemotherapy used for nasopharyngeal carcinoma (NPC), but some patients can't use it due to eligibility issues or past severe reactions.
  • A phase 2 trial tested the combination of gemcitabine and toripalimab on patients who couldn't take cisplatin, showing good results in terms of safety and effectiveness.
  • Out of 21 enrolled patients, the therapy had a 61.9% objective response rate and a perfect disease control rate, with manageable side effects like headaches and nausea.
View Article and Find Full Text PDF

Objective: Postradiation nasopharyngeal necrosis (PRNN) frequently develops after second-course radiotherapy for nasopharyngeal carcinoma (NPC). PRNN can lead to internal carotid artery (ICA) massive hemorrhage due to ICA rupture, resulting in sudden death. This study aims to explore the pretreatment of the ICA to prevent fatal massive hemorrhage in PRNN patients.

View Article and Find Full Text PDF
Article Synopsis
  • Endoscopic nasopharyngectomy (ENPG) is challenging for surgeons, leading to the development of low-temperature plasma radiofrequency ablation (LPRA) as a simpler surgical method for localized recurrent nasopharyngeal carcinoma (rNPC).
  • A study analyzed 56 rNPC patients who underwent LPRA surgery, which involved ablating from the tumor's edge to its center; outcomes showed significant survival rates with minimal complications.
  • Results indicated a high median overall survival rate of 92.9% and effective tumor removal with re-epithelialization in 96.4% of patients, suggesting LPRA is a promising alternative to traditional methods.
View Article and Find Full Text PDF
Article Synopsis
  • Locoregional radiotherapy, combined with chemotherapy, has improved survival rates for patients with de novo metastatic nasopharyngeal carcinoma (mNPC), but only 54% achieve a response after treatment.
  • A phase II study investigated the effect of adding a PD-1 inhibitor to standard treatment, finding an objective response rate of 81.8% among 22 enrolled patients after 3 months.
  • Despite the promising results, 68.2% of patients experienced severe side effects, and higher levels of Epstein-Barr virus DNA were linked to poorer progression-free survival.
View Article and Find Full Text PDF

Importance: Unlike substantial evidence in the prevention of chemotherapy-induced nausea and vomiting (CINV), research in the prevention of nausea and vomiting caused by concurrent chemoradiotherapy (CCRT) is currently lacking.

Objective: To compare the efficacy and safety of fosaprepitant weekly vs every 3 weeks for the prevention of nausea and emesis caused by CCRT among patients with nasopharyngeal carcinoma.

Design, Setting, And Participants: This pilot randomized clinical trial was conducted at a single cancer center from November 24, 2020, to July 26, 2021, among patients with nasopharyngeal carcinoma who had achieved CINV control after 2 to 3 cycles of induction chemotherapy.

View Article and Find Full Text PDF

Background: Treatment options for patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) are not clear after progression on previous treatment with PD-(L)1 inhibitor; critical gaps in evidence remain for such cases. Immunotherapy combined with antiangiogenic therapy has been reported to have synergistic antitumor activity. Therefore, we evaluated the efficacy and safety of camrelizumab plus famitinib in patients with RM-NPC who failed treatment with PD-1 inhibitor-containing regimens.

View Article and Find Full Text PDF

Background: The trajectories of health-related quality of life (HRQoL) of nasopharyngeal carcinoma (NPC) during and after the treatment along with their associated factors are seldom investigated in longitudinal studies. This study aims to investigate the longitudinal trajectories of HRQoL over time and their associated factors in patients with newly diagnosed NPC.

Methods: Between July 2018 and September 2019, a total of 500 patients were finally involved in this study.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to compare the effectiveness and safety of hyperfractionated radiotherapy versus standard fractionation for patients with advanced recurrent nasopharyngeal carcinoma who previously received high-dose radiation.
  • From July 2015 to December 2019, 144 eligible patients were enrolled in a phase 3 trial, with equal random assignment to either treatment group (72 each).
  • The primary goals were to assess severe late complications and overall survival, with findings indicating that hyperfractionation might reduce late toxicity compared to standard approaches.
View Article and Find Full Text PDF

Purpose: Immune checkpoint inhibitors combined with antiangiogenic therapy reportedly have potential synergistic antitumor activity. We investigated the activity and safety of this regimen for recurrent/metastatic nasopharyngeal carcinoma (NPC).

Methods: This single-arm, Simon two-stage study enrolled patients with recurrent/metastatic NPC who were refractory to at least first-line systemic therapy and treatment-naive to immune checkpoint inhibitors.

View Article and Find Full Text PDF
Article Synopsis
  • The study explored the effectiveness and safety of a combination therapy called GAT (gemcitabine, apatinib, and toripalimab) in treating recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) in 41 patients.
  • Results showed a high overall response rate of 90.2%, with median progression-free survival (PFS) of 25.8 months, although a significant number of patients (56.1%) experienced severe treatment-related side effects.
  • Identifying high-risk patients (such as those with previous radiation therapy) and monitoring specific tumor markers could help optimize treatment benefits and manage potential risks in this patient population.
View Article and Find Full Text PDF

Background: Studies of local therapy (LT) to metastatic foci from nasopharyngeal carcinoma (NPC) are inconsistent and controversial. Here, we aimed to explore the survival benefit of LT directed at metastatic foci from NPC.

Methods: A retrospective analysis was conducted in NPC patients with liver, lung, and/or bone metastases.

View Article and Find Full Text PDF

Importance: Induction chemotherapy added to concurrent chemoradiotherapy significantly improves survival for patients with locoregionally advanced nasopharyngeal carcinoma, but the optimal induction regimen remains unclear.

Objective: To determine whether induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) improves survival vs cisplatin and fluorouracil (PF) prior to chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma.

Design, Setting, And Participants: This randomized, open-label, phase 3 clinical trial recruited 238 patients at 4 hospitals in China from October 20, 2016, to August 29, 2019.

View Article and Find Full Text PDF

Purpose: Radiotherapy is the most important primary treatment for patients with nasopharyngeal carcinoma. Generally, the treatment duration of radiotherapy takes six or six and half weeks with 30 to 33 fractions. The current study was conducted to evaluate the association between prognosis and the duration of radiotherapy in nasopharyngeal carcinoma patients.

View Article and Find Full Text PDF

Background: Our previous trial confirmed that induction chemotherapy (IC) improved long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). In this study, we investigated the impact of IC on long-term quality of life (QoL) in this cohort.

Methods: Our trial was a randomised, open-label phase 3 trial comparing IC followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone in patients with stage III-IVB (except T3N0-1) NPC.

View Article and Find Full Text PDF

Objective: Salvage endoscopic nasopharyngectomy (ENPG) is a reasonable choice for resectable recurrent nasopharyngeal carcinoma (rNPC). However, in past decades, complete removal of the tumor was not feasible when the recurrent lesion was adjacent to the internal carotid artery (ICA). The present article introduces innovative strategies to ensure sufficient surgical margins while avoiding accidental injury to the ICA.

View Article and Find Full Text PDF

Biopsy is essential for some patients with suspected distant metastasis, so we aim to figure out whether biopsy of distant metastasis is associated with impaired survival in NPC. A total of 743 synchronous metastatic NPC patients from 2004 to 2016 were analyzed from the population-based Surveillance, Epidemiology, and End Results program. Propensity score matching was used to control confounders and create a well-balanced cohort.

View Article and Find Full Text PDF

Purpose: Previous studies suggest that a cumulative cisplatin dose of 200 mg/m might be adequate in the intensity-modulated radiation therapy (IMRT) era for locoregionally advanced nasopharyngeal carcinoma (LANPC). However, two cycles of once-every-3-weeks cisplatin at 100 mg/m has never been prospectively compared with standard once-a-week cisplatin regimen.

Patients And Methods: This trial was conducted at three hospitals from 2011 to 2016.

View Article and Find Full Text PDF
Article Synopsis
  • NPC patients with MHC I Class errors tend to have poor survival rates, suggesting that a lack of tumor neoantigens contributes to their ability to escape immune detection.
  • DNA and RNA sequencing of samples from 26 NPC patients uncovered a significant neoantigen load, with metastatic sites showing more severe depletion of these antigens compared to primary tumors.
  • A predictive model revealed distinct tumor subtypes; subtype I had reduced T cells and neoantigens, subtype II had high immune checkpoint expression with the least depletion, and subtype III was varied, highlighting the need for personalized treatment strategies using therapeutic vaccines.
View Article and Find Full Text PDF

Introduction: The current metastatic category (M) of nasopharyngeal carcinoma (NPC) is a "catch-all" category, we previously successfully established a M1 subdivision system based on prognostic metastatic characteristics in epidemic areas. We aimed to figure out metastatic characteristics associated with survival outcomes of NPC in non-epidemic areas.

Methods: A total of 428 newly diagnosed de novo metastatic NPC patients from 2010 to 2016 were analyzed from the population-based Surveillance, Epidemiology, and End Results program.

View Article and Find Full Text PDF

Background: The role of surgery compared with reirradiation in the primary treatment of patients with resectable, locally recurrent nasopharyngeal carcinoma (NPC) who have previously received radiotherapy is a matter of debate. In this trial, we compared the efficacy and safety outcomes of salvage endoscopic surgery versus intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent NPC.

Methods: This multicentre, open-label, randomised, controlled, phase 3 trial was done in three hospitals in southern China.

View Article and Find Full Text PDF

Objectives: Nasopharyngeal carcinoma (NPC) patients with retropharyngeal lymph node (RPLN) recurrence typically undergo reirradiation and experience severe radiotoxicity. Salvage open surgery is challenging because gaining access to the retropharyngeal space is complex and risky. Thus, only several centers can perform this procedure, and complications are common.

View Article and Find Full Text PDF

Background: Surgical access for retropharyngeal lymph node (RPLN) dissection is difficult. We aimed to examine the efficacy of transcervical endoscopic RPLN dissection (TSE-RPLND) for recurrent RPLN in nasopharyngeal carcinoma (NPC).

Methods: From April 2013 to February 2019, a total of 31 patients with NPC diagnosed with RPLN recurrence underwent TSE-RPLND.

View Article and Find Full Text PDF

Importance: The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear.

Objective: To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC.

Design, Setting, And Participants: Patients with biopsy-proven mNPC, who demonstrated complete or partial response (RECIST v1.

View Article and Find Full Text PDF

Background: To assess the efficacy of Nimotuzumab in combination with first-line chemoradiotherapy treatment in Chinese patients with primary III-IVb stage nasopharyngeal carcinoma.

Methods: Patients with primary locoregionally advanced nasopharyngeal carcinoma who were treated with intensity-modulated radiotherapy (IMRT) and concurrent cisplatin-based chemotherapy between January 2008 and December 2013 at a single institution were retrospectively reviewed. Group A received at least 6 doses of Nimotuzumab, while Group B did not receive Nimotuzumab.

View Article and Find Full Text PDF